Trials that use: Cox proportional-hazards model
New to this method? Read the tutorial →
399 results
- Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL: Complete Statistical AnalysisIndependent statistical analysis of Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission: Complete Statistical AnalysisIndependent statistical analysis of OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission: primary endpoint results,…
- OPTIMISEIndependent statistical analysis of Occipital Nerve Stimulation (ONS) for Migraine: OPTIMISE: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01775735).
- OPTIMIZEComplete statistical analysis of the OPTIMIZE phase 3 trial of roflumilast dosing as add-on to standard COPD treatment in severe COPD, including trial design, discontinuation endpoints, logistic and Cox regression, adverse events,…
- OptiVol® Care Pathway: Complete Statistical AnalysisIndependent statistical analysis of OptiVol® Care Pathway: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00847288).
- ORCHARRDIndependent statistical analysis of Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma: primary endpoint results, effect estimate with confidence interval,…
- OReOIndependent statistical analysis of A Study to Examine Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- ORIGINComplete statistical analysis of the ORIGIN phase 3 trial, including its factorial design, cardiovascular and diabetes endpoints, Cox and log-rank methods, odds ratios, confidence intervals, and statistical interpretation.
- Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors: Complete Statistical AnalysisIndependent statistical analysis of Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors: primary endpoint results, effect estimate with confidence…
- Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer: Complete Statistical AnalysisIndependent statistical analysis of Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer: primary endpoint results, effect estimate with confidence…
- Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma: Complete Statistical AnalysisIndependent statistical analysis of Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04209686).
- Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3): Complete Statistical AnalysisIndependent statistical analysis of Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Paracetamol With Caffeine to Treat Episodic Tension Type Headache: Complete Statistical AnalysisIndependent statistical analysis of Paracetamol With Caffeine to Treat Episodic Tension Type Headache: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01755702).
- Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC): Complete Statistical AnalysisIndependent statistical analysis of Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01392183).
- PEAKIndependent statistical analysis of the PEAK trial comparing panitumumab plus mFOLFOX6 with bevacizumab plus mFOLFOX6 for first-line treatment of metastatic colorectal cancer with wild-type KRAS tumors. Includes progression-free survival, overall survival, response…
- PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors: Complete Statistical AnalysisIndependent statistical analysis of PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors: primary endpoint…
- Peginterferon α-2b as a Maintenance Therapy in Participants With Multiple Myeloma Who Responded to Induction Therapy (P01972-AM7): Complete Statistical AnalysisIndependent statistical analysis of Peginterferon α-2b as a Maintenance Therapy in Participants With Multiple Myeloma Who Responded to Induction Therapy (P01972-AM7): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Pembrolizumab in Treating Patients With High Risk Oral Intraepithelial Neoplasia: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab in Treating Patients With High Risk Oral Intraepithelial Neoplasia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02882282).
- Pemetrexed Disodium With or Without Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV or Recurrent Non-Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Pemetrexed Disodium With or Without Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV or Recurrent Non-Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size…
- PEPSIndependent statistical analysis of Prevention of Peritonitis in Peritoneal Dialysis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01293799).
- PERSISTIndependent statistical analysis of Bipolar Maintenance Study of Lurasidone Adjunctive to Lithium or Divalproex: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01358357).
- Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM): Complete Statistical AnalysisIndependent statistical analysis of Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Phase II Study of Interleukin-21 (rIL-21) vs Dacarbazine (DTIC) in Patients With Metastatic or Recurrent Melanoma: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of Interleukin-21 (rIL-21) vs Dacarbazine (DTIC) in Patients With Metastatic or Recurrent Melanoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Phase II Trial of EVEROLIMUS ± Trastuzumab in Hormone-Refractory Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase II Trial of EVEROLIMUS ± Trastuzumab in Hormone-Refractory Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas: Complete Statistical AnalysisIndependent statistical analysis of Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Phase III Study of S-1 + Cisplatin vs Cisplatin in Cervical Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase III Study of S-1 + Cisplatin vs Cisplatin in Cervical Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- PIONEER 6Independent statistical analysis of PIONEER 6, the randomized phase 3 trial of oral semaglutide versus placebo in subjects with type 2 diabetes, including its MACE endpoint, non-inferiority analysis, Cox model, hazard ratio,…
- PIX-RIndependent statistical analysis of Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are…
- PLANE-PCIndependent statistical analysis of Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04848337).
- PrE0801Independent statistical analysis of NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition at Recurrence After Adjuvant Therapy in Renal Cell Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- PRELUDE:Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin: Complete Statistical AnalysisIndependent statistical analysis of PRELUDE:Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- PRESIDEIndependent statistical analysis of A Study to Assess the Benefit of Treatment Beyond Progression With Enzalutamide in Men Who Are Starting Treatment With Docetaxel After Worsening of Their Prostate Cancer When Taking…
- PREVENT-HDIndependent statistical analysis of A Study of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With Acute, Symptomatic Coronavirus Disease 2019…
- Preventing Sexual Transmission of HIV With Anti-HIV Drugs: Complete Statistical AnalysisIndependent statistical analysis of Preventing Sexual Transmission of HIV With Anti-HIV Drugs: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00074581).
- PRIORITIIndependent statistical analysis of A Study of Immediate 9 Months Adjuvant Hormone Therapy With Triptorelin 11.25 mg Versus Active Surveillance After Radical Prostatectomy in High Risk Prostate Cancer Patients.: primary endpoint results,…
- PROSELICAA detailed statistical analysis of the phase 3 PROSELICA trial comparing cabazitaxel 20 mg/m² with 25 mg/m² plus prednisone in metastatic castration resistant prostate cancer, including non-inferiority methodology, overall survival, progression endpoints,…
- ProspectIndependent statistical analysis of A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer: primary endpoint results, effect estimate with…
- R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas: Complete Statistical AnalysisIndependent statistical analysis of R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- RA-BRANCHIndependent statistical analysis of A Study of Baricitinib in Participants With Rheumatoid Arthritis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04086745).
- RAD001 Plus Bevacizumab in Metastatic Melanoma: Complete Statistical AnalysisIndependent statistical analysis of RAD001 Plus Bevacizumab in Metastatic Melanoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00591734).
- Radiation Therapy (RT) and Temozolomide (TMZ) in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma: Complete Statistical AnalysisIndependent statistical analysis of Radiation Therapy (RT) and Temozolomide (TMZ) in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Radiation Therapy Alone for the Treatment of Stage 1 and 2 Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Radiation Therapy Alone for the Treatment of Stage 1 and 2 Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Randomized Trial of Topotecan With M6620, an ATR Kinase Inhibitor, in Small Cell Lung Cancers and Small Cell Cancers Outside of the Lungs: Complete Statistical AnalysisIndependent statistical analysis of Randomized Trial of Topotecan With M6620, an ATR Kinase Inhibitor, in Small Cell Lung Cancers and Small Cell Cancers Outside of the Lungs: primary endpoint results, effect estimate…
- Rapid Diagnostic Assay for Gonorrhea and Chlamydia: Complete Statistical AnalysisIndependent statistical analysis of Rapid Diagnostic Assay for Gonorrhea and Chlamydia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05564299).
- Rate Control Versus Rhythm Control For Postoperative Atrial Fibrillation: Complete Statistical AnalysisIndependent statistical analysis of Rate Control Versus Rhythm Control For Postoperative Atrial Fibrillation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02132767).
- RE-COVER IComplete statistical analysis of RE-COVER I, the randomized phase 3 trial comparing dabigatran 150 mg with warfarin for 6 months in patients with acute symptomatic venous thromboembolism, including non-inferiority methodology, time-to-event analyses,…
- RE-MEDYA detailed statistical analysis of the randomized phase 3 RE-MEDY trial comparing dabigatran with warfarin for secondary prevention of venous thromboembolism, including time-to-event methodology, non-inferiority analysis, bleeding outcomes, and statistical interpretation.
- Real-World Effectiveness of Palbociclib in Combination With an Aromatase Inhibitor: Complete Statistical AnalysisIndependent statistical analysis of Real-World Effectiveness of Palbociclib in Combination With an Aromatase Inhibitor: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05361655).
- Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.: Complete Statistical AnalysisIndependent statistical analysis of Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.: primary endpoint results,…
- Real-world Treatment Patterns and Effectiveness of Palbociclib and AI Therapy: Complete Statistical AnalysisIndependent statistical analysis of Real-world Treatment Patterns and Effectiveness of Palbociclib and AI Therapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04176354).